Parexel adds clinical logistics sites in Singapore & Russia

By Nick Taylor

- Last updated on GMT

Related tags: Management, Tgn1412, Clinical trial

Parexel has opened clinical logistics services facilities in Singapore and Russia to meet increasing demand for support in the emerging regions.

Adding the depot in Singapore and ancillary warehouse in Russia allows Parexel to better manage clients’ trial supply requirements in Asia Pacific and Central and Eastern Europe. Parexel chose to strengthen in these locations because of increasing client demand in the regions.

"The opening of these new facilities within our global clinical logistics services infrastructure positions us to meet increasing client demand for high quality clinical trial supplies handling and transport in emerging regions​", said Joe Avellone, corporate vice president at Parexel.

Singapore benefits from “best-in-class transportation performance and favourable import/export regulations​” making it a good location from which to serve Asia Pacific, said Avellone.

The depot has “ambient, cold, and frozen storage for investigational medicines and other trial-specific materials, as well as inventory management, distribution, returns, and destruction​”, a company spokesperson told Outsourcing-Pharma.

Other features include 24/7/365 environment monitoring, a central alarm system, and backup power.


The site in Russia handles non-drug material required for clinical trials, such as lab kits, medical equipment and documents. Expanding its presence in Russia will help Parexel cut costs and transport time for clients, claims the company.

Parexel’s own logistics experts organise the importation, as opposed to managing external vendors for storage, which often take longer to get clinical trial materials into the country​”, said the spokesperson.

Keeping all logistics in-house allows Parexel to better manage its warehousing infrastructure and streamline the supply chain, said the spokesperson. This is particularly beneficial in Russia where study materials need to be imported well in advance of distribution to investigational sites.

Parexel declined to quantify savings to Outsourcing-Pharma.

Related news

Show more

Related product

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more